# Shared effector genes of insomnia, anxiety and depression implicate synaptic processes as transdiagnostic drug targets

Marijn Schipper[1], Alexey A. Shadrin[2], Cato Romero[3], Eleni Friligkou[4,5], Renato Polimanti[4,5,6,7], Danielle Posthuma[1,8], Eus J.W. Van Someren[9*], Elleke Tissink[9*]

[*] These authors jointly supervised this work

[1] Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam 1081 HV, The Netherlands

[2] Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

[3] Department of Child and Adolescent Psychiatry and Psychology, Section Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center, Amsterdam UMC, Amsterdam, the Netherlands

[4] Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

[5] VA CT Healthcare Center, West Haven, CT, USA

[6] Wu Tsai Institute, Yale University, New Haven, CT, USA

[7] Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

[8] Department of Clinical Genetics, Section Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center, Amsterdam University Medical Centre, Amsterdam 1081 HZ, The Netherlands

[9] Department of Sleep and Cognition, Netherlands Institute for Neuroscience, an institute of the Royal Netherlands Academy of Arts and Sciences, The Netherlands

✉ Correspondence: e.tissink@nin.knaw.nl

**Abstract**

Insomnia (INS) is a major factor determining the risk, severity, treatment resistance and relapse of depression (DEP) and anxiety disorders (ANX), suggesting a shared neurobiological vulnerability. Identifying common biological mechanisms that are therapeutically actionable is a foundational step towards improving current clinical care. Since INS, DEP, and ANX share a substantial proportion of their genetic risk, pinpointing the specific genetic factors that influence these three conditions simultaneously offers a route to discover pharmacological targets with transdiagnostic potential. We developed a novel framework of multi-level trivariate genetic analysis to identify the shared genetic component of INS, DEP and ANX using genome-wide association studies (GWAS). We trace shared components through global and local genetic correlations, overlapping genome-wide significant loci, shared effector genes, and variants with shared effects. We show that 55% of the genetic signal is shared across all three conditions. We identify 195 genomic loci with shared signal for at least two conditions, many of which are likely arising from the same causal variant (at least 50%) or effector gene (60-80%). Pairwise mediation analyses suggest that these shared likely causal variants are more consistent with models of vertical pleiotropy where DEP and INS are risk factors towards ANX, rather than with models of horizontal pleiotropy. We find convergence of shared effector genes on biological processes such as inhibitory synaptic transmission, neuronal organization, and axonal development. We find that the majority of shared effector genes that are also druggable are involved in synaptic transmission and located in synaptic membranes, identifying *CACNA2D3*, *DRD2*, *GRIA1* and *GRM5* as key targets for drug development to treat comorbid INS, DEP and ANX. These results reveal an interconnected but mechanistically diverse basis for shared genetic risk across INS, DEP and ANX, and offer potential candidates for future pathway-tailored transdiagnostic therapeutic targets.

## Introduction

One-third of the general population has difficulties falling or staying asleep, which can severely impact quality of life when manifesting frequently and persistently as insomnia disorder (INS)[1]. INS may develop as a symptom of another condition, such as depression (DEP) or anxiety disorders (ANX), or can alternatively precede and increase the risk of developing these conditions[2,3]. INS, DEP and ANX are the mental health conditions with the highest 12-month prevalence (7%, 6.9%, and 14% respectively)[4], yet show moderate response rates to existing treatment options[5], underscoring the need to investigate alternative therapeutic targets that could potentially benefit millions of people worldwide. Since INS, DEP and ANX show high rates of lifetime multimorbidity[6], transdiagnostic intervention efficacy[7], and a shared neurobiological vulnerability circuit[8], it is suggested that a common aetiology may underlie INS, DEP, and ANX. Finding such common biological mechanism(s) may guide the development of transdiagnostic treatments that target these shared vulnerabilities, potentially improving outcomes across multiple conditions simultaneously[9,10]. Novel pharmacological developments are about 2.6 times more successful when supported by genetic evidence[11]. However, the molecular genetic signal specifically shared across the triad of INS, DEP, and ANX has not been studied systematically to date.

Based on decades of twin research[12], it is widely recognized that the heritability of INS (39%[13]), DEP (37%[14]), ANX (32%[15]) is largely shared (>50% for DEP, complete for ANX). More recently, the molecular genetic signals of INS[16], ANX[17,18], and DEP[19,20] have been intensively investigated in genome-wide association studies (GWAS). These studies confirm a similar genetic architecture across the three conditions based on common genetic variants, i.e. single nucleotide polymorphisms (SNPs). That is, the phenotypic variance in INS, ANX, or DEP that can be explained by additive effects of SNPs (i.e. observed SNP-heritability, $h^2_{\mathrm{SNP}}$) is modest (6-7%[17,20,21]), and can be captured by ~12,000 putatively causal SNPs with fairly low effect sizes compared to other psychiatric disorders[22]. The degree to which these SNPs overlap and their effect sizes correlate (i.e. genetic overlap and genetic correlation [$r_g$] respectively) can be a statistical byproduct of methodological artefacts (i.e. phenotype misclassification[23]) or can point to real shared genetic risk. Previous studies show extensive genetic correlation and overlap between DEP and ANX ($r_g$ = .87[24], and 85-95% of putative causal SNPs shared, with 82-91% sign concordance[17,20,25]). Comparisons with INS are often omitted[24,26,27], but two bivariate studies report the genetic overlap between DEP and INS to be 65%[28,29], and one cross-disorder study estimates the genetic correlations of INS with DEP and ANX to be $r_g$ = .35 and .45 respectively[22].

Since the odds of successful drug development improve with increasing genetic evidence that the target gene is causal[11], it is important to move beyond global effects and pinpoint where in the genome likely causal effects between genetically correlated traits co-occur. We therefore propose a novel multi-layer analysis framework to trace down onto which biological mechanisms likely-causal genetic effects

83 converge. Firstly, we identify shared genome-wide significant loci, and loci with significant local genetic
84 correlations. This leverages recent advances in GWAS power for these traits, and genetic correlation
85 analysis methods. Shared loci and non-zero (local) genetic correlations between INS, DEP, and ANX would
86 indicate the presence of pleiotropy[30–32]: the statistical association of one SNP or gene with multiple traits.
87 Secondly, we identify pleiotropic variants and genes through colocalization analysis[33] and effector gene
88 prediction[34] within these loci. Lastly, we analyse how these variants affect multiple traits independently
89 (i.e. biological or horizontal pleiotropy) or through a causal pathway (i.e. mediation or vertical pleiotropy)[35].
90 To this end we deploy a novel variant-level extension[36] of trait-level causal inference methodology using
91 genetic instruments (i.e. Mendelian Randomization) to classify SNPs as likely confounding, horizontal or
92 vertical pleiotropic. Observing in which direction potential vertical pleiotropic variants act would refine
93 previous trait-level results[37,38], since trait-level bidirectionality is most plausibly understood as a mixture of
94 unidirectional variant-level effects. Variant-level pleiotropy could ultimately inform which potential drug
95 targets could achieve transdiagnostic therapeutic effects through either the same upstream pathway or
96 multiple divergent pathways.
97 Using this framework, we discover shared biological pathways with targets for potential
98 transdiagnostic treatment across INS, DEP and ANX. At the highest level, we estimate the global trivariate
99 genetic overlap to be 55%, and subsequently identify 195 unique loci of shared genome-wide significance
100 or correlating genetic signal for at least two traits. We then show that at least 50% and 60-80% of these loci
101 also share the same likely causal variant or effector gene respectively, and observe that these variants are
102 most compatible with models of vertical pleiotropy. We use our findings to search for convergence of
103 implicated biology across ANX, DEP and INS and find that shared effector genes are almost exclusively
104 involved in inhibitory synaptic transmission and organization, and neuronal and axonal development.
105 Moreover, we find that the majority of our shared effector genes that have previously been investigated or
106 approved as drug targets are indicated for INS, DEP and/or ANX, many of which are involved in the same
107 synaptic transmission pathways. Altogether, we show that many genomic regions associated with INS, DEP
108 and ANX map to the same likely causal variants showing effects consistent with vertical pleiotropy, and
109 map to shared genes that converge on shared biological pathways being potentially therapeutically
110 actionable.
111
112 **Results**
113 Our analyses are based on previously published GWAS summary statistics for ANX[17], DEP[19,20] and INS[21],
114 (Supplementary Table 1, supplementary note 1). The original studies had an effective sample size of $N_{INS}$
115 = 1,114,549, $N_{ANX}$ = 529,764, $N_{DEP}$ = 1,061,269 based on individuals of European (EUR) and African
116 (AFR; $N_{ANX}$ = 80,104; $N_{DEP}$ = 132,002) genetic ancestry, and also performed cross-ancestry meta-analyses

($N_{ANX}$ = 627,041; $N_{DEP}$ = 1,118,664). We obtained access through public and restricted data access protocols (see Methods). With these data, we investigated the genetic relationship between INS, ANX and DEP on a genome-wide, locus, and causal gene/variant level.

*Trivariate genetic overlap on the genome-wide level*

Combined genome-wide analysis of all three phenotypes in a trivariate approach has not been performed previously, but has the potential to distinguish the portion of genetic overlap shared between all three conditions, and the proportion of genetic overlap unique to each pair of conditions[39]. We therefore modeled genome-wide genetic overlap across three traits simultaneously using Trivariate MiXeR[39], a recently developed extension of the established univariate and bivariate Gaussian mixture models[40,41]. When applied on EUR GWAS summary statistics, we observed a genetic overlap of 55% across all three traits (Figure 1a). The genetic signal of INS overlapping with DEP and with ANX was of comparable size (78% and 79% respectively) and concerned the same SNPs, since 98% of DEP overlapped with ANX (Supplementary Table 2). However, the correlation of effect sizes within the overlap was stronger between INS and ANX ($r_{\text{g-shared}}$ = .85, SD =.09) than between INS and DEP ($r_{\text{g-shared}}$ = .63, SD = .04). As expected based on previous studies[17,20,24,25], the strongest correlation of effect sizes was observed for the overlapping SNPs between DEP and ANX ($r_{\text{g-shared}}$ = .94, SD = .04). Notably, 21% of INS variants were not shared with ANX or DEP. While ANX also contained a unique genetic component, this was accompanied by larger polygenicity (number of non-null SNPs; $\pi_{ANX}$ = 14,463; $\pi_{DEP}$ = 12,474, $\pi_{INS}$ = 12,180; Supplementary Table 2).

These results deepen findings from standard global genetic correlations ($r_g$) estimated with LD Score regression[42] (LDSC; $r_{g_{INS\text{-}DEP}}$ = .63 [SE = .01], $r_{g_{INS\text{-}ANX}}$ = 0.63 [SE = .02]; $r_{g_{DEP\text{-}ANX}}$ = .91 [SE = .01]). Given the considerable trivariate genetic overlap that we observed, we aimed to quantify the contribution of each trait in explaining the $r_g$ between the other two conditions. (Figure 1b). Using a novel LDSC extension, partial LDSC[43], we find that accounting for the SNP effects of INS significantly reduces the genetic correlation between DEP and ANX to $r_{g_{DEP\text{-}ANX\,|\,INS}}$ = .87 (SE = .04, $T_{diff}$ = 3.27, $p_{diff}$ = $1.07\times10^{-3}$). As expected from the strong correlation between DEP and ANX, conditioning the DEP-INS correlation on ANX and the ANX-INS correlation on DEP greatly reduces the found genetic correlation ($r_{g_{INS\text{-}ANX\,|\,DEP}}$ = .17 [SE = .08]; $r_{g_{INS\text{-}DEP\,|\,ANX}}$ = .16 [SE = .08]). Altogether, these genome-wide results show that a significant proportion of the genetic overlap between ANX and DEP also extends to INS, whilst INS also contains a distinct genetic component.




*Figure 1.* **The genome-wide genetic overlap of INS, ANX and DEP.** a) Trivariate overlap estimated with MiX3R (Supplementary Table 2). Each circle (i.e. trait) has a size proportional to the number of trait-influencing variants (i.e. polygenicity) and overlapping areas proportional to the number of variants shared among respective traits. Percentages in the diagram are given with respect to the combined total area of all three traits (and sum to 101% due to rounding). b) Genetic correlations based on LDSC (global $r_g$ with SE) and Trivariate MiXeR (shared $r_g$ with SD). The partial $r_g$ (with SE) between two traits depends on conditioning on the third trait.

*Identifying pleiotropic loci across conditions*

We then aimed to move beyond global patterns and identify the genomic loci with shared genetic signal. First, we investigated which genome-wide significant loci ($p < 5 \times 10^{-8}$) were physically overlapping across traits. The EUR GWAS summary statistics included 40, 235, and 248 genome-wide significant (GWS) loci for ANX[17], DEP[20] and INS[21] respectively, based on the FUMA definition[44]. Cross-ancestry GWAS summary statistics of ANX[17] and DEP[19] included 10 and 47 genome-wide significant loci, respectively, that were not identified in the EUR-only analyses. One locus was GWS in the AFR summary statistics for ANX[17], none for DEP[19]. This totals 580 GWS loci in our three traits across these ancestries.

Thirty-two percent of these loci were overlapping with at least one locus of another phenotype in the triad, spanning 87 unique locations in the genome. Of all EUR and cross-ancestry loci (Supplementary Table 3), nine overlapped across all three phenotypes, 49 physically overlapped between INS and DEP, 26 between DEP and ANX, and three between INS and ANX (Figure 2; Supplementary Table 4). The GWS locus of ANX in the AFR sample did not overlap with any locus of DEP or INS.




*Figure 2.* **Loci with shared genetic signal across ANX, DEP and INS.** Ideogram with each chromosome showing the location of genome-wide significant loci (dark grey lines) that were physically overlapping across INS, DEP and ANX GWAS summary statistics (both EUR or cross-ancestry, or EUR for INS and cross-ancestry for DEP/ANX). Markers connected by grey lines had significant correlating GWAS signal across trait pairs (i.e. identified through LAVA). See Supplementary Table 3-6 for the accompanying statistics.

Second, we explored regions that had significant univariate signal and bivariate local genetic correlations. We applied LAVA[45] to perform local genetic correlation analysis to the EUR summary statistics. The non-overlapping genomic regions ($n$ = 2,495; defined in Methods) were first screened for sufficient univariate genetic signal in each trait (local observed $h^2_{SNP}$; 582 regions survived $p_{univ} < 1\times10^{-4}$, a threshold used in previous work[46–48]) before bivariate genetic correlations between INS and ANX, INS and DEP, and/or ANX and DEP were estimated. Local $r_g$ estimates were significant after correcting for multiple testing ($p_{bivar} < .05 / 582 = 8.59 \times10^{-5}$) in ten EUR loci for all three trait pairs (Supplementary Table 5-6). Seventeen loci were significant for INS-DEP as well as DEP-ANX, and 3 loci showed significant local $r_g$ between both INS-ANX and DEP-ANX. Most loci were only significant for one trait pair: 46 between INS and DEP, five between INS and ANX, and 27 between ANX and DEP.

Of all 108 unique EUR LAVA-identified loci, $n$ = 39 loci physically overlapped with any shared GWS locus described above. These LAVA regions were almost always identified for the same trait pair or

188 for the same and additional trait pairs as the GWS locus (Supplementary Table 6). In total, 195 loci were
189 identified to be shared across at least one trait pair ($n_{GWS}$ = 87, $n_{LAVA}$ = 108), which could be reduced to 146
190 unique locations given the overlap across approaches. We continued our downstream analyses with all 195
191 loci with cross-disorder evidence.
192
193 *Identifying putative causal variants*
194 We aimed to identify shared putative causal variants by testing each of the shared 195 loci identified above
195 for having an observed genetic signal consistent with a shared causal variant. For this purpose, we ran
196 colocalization analysis with COLOC[33] on the GWS and LAVA significant loci for each relevant trait pair.
197 These loci colocalized to the same variants in 50% of locus pairs. Thirteen loci showed colocalization
198 evidence across all three traits (Table 1).
199 The percentage of significant colocalization is higher (62%) in the GWS loci than in the LAVA
200 loci (42%), which is a significant difference (Fisher's exact test, $p = 1.5\times10^{-3}$). This discrepancy can be
201 explained by (1) LAVA loci generally being larger than GWS loci allowing for different signals residing
202 within the same region, and/or (2) a lack of power. All our LAVA loci were significant in the univariate
203 test of local heritability ($p_{univ} < 1\times10^{-4}$), yet for these loci, the COLOC posterior probability for at least one
204 trait having no signal for a causal variant in the locus is, on average, 34% compared to 7% for GWS
205 significant loci. Of the remaining posterior probability, on average, 64% of the probability points to
206 colocalization, whereas 36% of the probability points to non-colocalizing signal for both traits. These
207 probabilities are highly similar (65% and 35% respectively) for GWS loci. This might indicate that the
208 COLOC analysis based on LAVA loci is hindered by statistical power, and the colocalization estimate in
209 the LAVA loci might be too conservative.
210 Across all loci (GWS and LAVA), the average proportion of colocalization probability is 64% vs.
211 36% non-colocalization probability when signal is detected for both traits. This suggests that the signal
212 observed in about two thirds of the overlapping GWS and LAVA loci is consistent with a shared causal
213 variant.
214
215 *Distinguishing horizontal from vertical pleiotropy*
216 We performed an exploratory analysis to investigate whether different forms of pleiotropy (i.e. vertical,
217 horizontal, or confounding) could be distinguished among the 95 colocalizing variants. For this purpose we
218 used variant-level PRISM's[36] pairwise analyses (see Methods), which is based on the trait-level LHC-MR[49]
219 framework. LHC-MR assumes classical Mendelian Randomization assumptions but allows for the
220 modelling of a genetic confounder. All of the 86 variants that successfully completed the PRISM pipeline
221 were assigned to models consistent with pairwise vertical pleiotropy (i.e., a direct effect on one trait and a

Table 1. *Overview of loci with pleiotropic evidence on the gene or variant level across all three traits. LAVA regions without significant local $h^2$ or loci being unresolved by FLAMES are left blank (-). H4 = posterior probability for the hypothesis that both traits are associated and share a single causal variant. Loci that overlap across traits or metric that pass a certain (e.g. significance) threshold are printed in bold. Without colocalization evidence, we did not perform variant-level mediation analyses (-).*

| Trait | Ancestry | GWS locus (Chr:Start:End) | Gene | Traitpair | Genetic correlation (EUR) | | | Colocalization | | Variant-level pleiotropy (EUR) |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | Region | $r_g$ | *P* | H4 | Top SNP | |
| INS | EUR | **1:72512988:74077588** | *NEGR1 / LRRIQ3* | INS-DEP | Chr 1, BP | .88 | **$5.17\times10^{-12}$** | .47 | - | - |
| | | | | INS-ANX | 72513120: | .85 | **$2.20\times10^{-7}$** | .00 | - | - |
| DEP | EUR | **1:73307570:73991792** | *NEGR1 / LRRIQ3* | DEP-ANX | 73992170 | .97 | **$7.31\times10^{-10}$** | .00 | - | - |
| | | | | INS-DEP | Chr 1, BP | .56 | **$5.56\times10^{-5}$** | .41 | - | - |
| ANX | EUR | **1:73766431:73991651** | *LRRIQ3* | INS-ANX | 73992171: | .73 | **$1.04\times10^{-6}$** | **.77** | rs61767168 | *NA* |
| | | | | DEP-ANX | 75132092 | .76 | **$2.72\times10^{-6}$** | **.94** | rs7540134 | DEP → ANX |
| INS | EUR | - | *ARHGAP15* | INS-DEP | Chr 2, BP | .82 | **$6.95\times10^{-5}$** | .03 | - | - |
| DEP | EUR | **2:144146675:144248905** | *ARHGAP15* | INS-ANX | 143259781: | .80 | **$5.74\times10^{-7}$** | .01 | - | - |
| ANX | EUR | **2:144145478:144272229** | *ARHGAP15* | DEP-ANX | 144503688 | 1.0 | **$1.06\times10^{-6}$** | **.96** | rs1320139 | DEP → ANX |
| INS | EUR | 3:71433554:71474216 | *FOXP1* | INS-DEP | Chr 3, BP | .34 | $3.42\times10^{-3}$ | - | - | - |
| DEP | EUR | 3:71748419:71820969 | *FOXP1* | INS-ANX | 71223282: | .75 | **$6.04\times10^{-7}$** | .00 | - | - |
| ANX | EUR | - | *FOXP1* | DEP-ANX | 72334704 | .68 | **$7.67\times10^{-5}$** | **.53** | rs1617010 | DEP → ANX |
| INS | EUR | - | *LPHN3* | INS-DEP | Chr 4, BP | .72 | **$6.67\times10^{-5}$** | .01 | - | - |
| DEP | EUR | - | *LPHN3* | INS-ANX | 61971162: | .41 | $2.20\times10^{-2}$ | - | - | - |
| ANX | EUR | - | *LPHN3* | DEP-ANX | 63337954 | .93 | **$1.71\times10^{-6}$** | .01 | - | - |
| INS | EUR | **5:92995013:93494731** | *NR2F1* | INS-DEP | Chr 5, BP | .51 | $4.96\times10^{-4}$ | **.91** | rs72786643 | INS → DEP |
| DEP | Cross | **5: 92788598:93288598** | *NR2F1* | INS-ANX | 91956906: | - | - | - | - | - |
| ANX | EUR | **5:92377803:92487543** | *NR2F1* | DEP-ANX | 93814604 | - | - | **.88** | rs10078721 | DEP → ANX |
| INS | EUR | - | *ZNF608* | INS-DEP | | .69 | **$6.47\times10^{-6}$** | .03 | - | - |
| DEP | EUR | 5:124203948:124308088<br>5:124896039:124955099 | *ZNF608* | INS-ANX | Chr 5, BP<br>124109486: | .91 | **$3.02\times10^{-7}$** | .00 | - | - |
| ANX | EUR | - | *ZNF608* | DEP-ANX | 125131720 | 1.0 | **$3.03\times10^{-9}$** | .02 | - | - |
| INS | EUR | **7:1928823:2003043** | - | INS-DEP | Chr 7, BP | .38 | $3.13\times10^{-3}$ | **.73** | rs868754 | DEP → INS |
| DEP | EUR | **7:1860733:2110850** | - | INS-ANX | 1366973: | - | - | **.70** | rs11773627 | INS → ANX |
| ANX | EUR | **7:1855531:2110850** | - | DEP-ANX | 2473749 | - | - | **.96** | rs868754 | DEP → ANX |
| INS | EUR | **7: 113772805:114348256** | *FOXP2* | INS-DEP | Chr 7, BP | .70 | **$2.32\times10^{-8}$** | **.99** | rs8180817 | *NA* |
| DEP | EUR | **7:114015707:114194615** | *FOXP2* | INS-ANX | 113339387: | .79 | **$5.74\times10^{-7}$** | **.99** | rs8180817 | *NA* |
| ANX | EUR | **7:114015707:114194615** | *FOXP2* | DEP-ANX | 115321301 | .98 | **$4.19\times10^{-8}$** | **.99** | rs8180817 | *NA* |
| INS | EUR | **9:14534422:14534505** | *NFIB* | INS-DEP | Chr 9, BP | .63 | **$2.32\times10^{-5}$** | .06 | - | - |
| DEP | Cross | **9:14401283:14901283** | *NFIB / ZDHHC21* | INS-ANX | 14244748: | .47 | $3.97\times10^{-3}$ | - | - | - |
| ANX | Cross | **9:14439816:14466354** | *NFIB* | DEP-ANX | 14902924 | .90 | **$2.07\times10^{-7}$** | .05 | - | - |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| INS | EUR | **11:99064188:99200206** | *CNTN5* | INS-DEP | Chr 11, BP | .66 | $4.23\times10^{-4}$ | .01 | - | - |
| DEP | Cross | **11:98891095:99391095** | *CNTN5* | INS-ANX | 98929381: | .85 | $\mathbf{7.21\times10^{-5}}$ | .03 | - | - |
| ANX | Cross | **11:99083930:99141095** | *CNTN5* | DEP-ANX | 99619347 | .94 | $\mathbf{1.28\times10^{-5}}$ | **.98** | rs2510682 | DEP → ANX |
| INS | EUR | **11:57369008:57681828** | - | INS-DEP | Chr 11, BP | .79 | $\mathbf{1.97\times10^{-6}}$ | **.96** | rs2509805 | *NA* |
| DEP | EUR | **11:57404779:57681828** | *CTNND1* | INS-ANX | 56623495: | .69 | $2.98\times10^{-4}$ | **.95** | rs12790660 | INS → ANX |
| ANX | EUR | **11:57385856:57681828** | - | DEP-ANX | 57675986 | 1.0 | $\mathbf{1.28\times10^{-6}}$ | **.97** | rs673344 | *NA* |
| INS | EUR | - | *NCAM1* | INS-DEP | Chr 11, BP | .87 | $\mathbf{1.66\times10^{-7}}$ | .01 | - | - |
| DEP | EUR | **11:112826867:112922254** | *NCAM1* | INS-ANX | 112755447: | .71 | $1.27\times10^{-4}$ | - | - | - |
| ANX | EUR | **11:112826867:112922254** | *NCAM1* | DEP-ANX | 113889019 | 1.0 | $\mathbf{4.33\times10^{-15}}$ | **.95** | rs2298527 | DEP → ANX |
| INS | EUR | - | *HMBG1* | INS-DEP | Chr 13, BP | .72 | $\mathbf{6.65\times10^{-5}}$ | .00 | - | - |
| DEP | EUR | - | *HMBG1* | INS-ANX | 30068526: | .68 | $3.09\times10^{-4}$ | - | - | - |
| ANX | EUR | - | *HMBG1* | DEP-ANX | 31433218 | .84 | $\mathbf{4.46\times10^{-6}}$ | .00 | - | - |
| INS | EUR | **15:91403674:91437388** | *FURIN* | INS-DEP | Chr 15, BP | .72 | $\mathbf{9.62\times10^{-6}}$ | **.99** | rs4702 | INS → DEP |
| DEP | EUR | **15:91416550:91429042** | *FURIN* | INS-ANX | 90632719: | - | - | **.99** | rs4702 | INS → ANX |
| ANX | EUR | **15:91416550:91429042** | *FURIN* | DEP-ANX | 91593623 | - | - | **.99** | rs4702 | DEP → ANX |
| INS | EUR | 16:51163120:51190740 | *SALL1* | INS-DEP | Chr 16, BP | .49 | $\mathbf{9.78\times10^{-6}}$ | **.98** | rs11645288 | INS → DEP |
| DEP | EUR | 16:51460871:51490422 | *SALL1* | INS-ANX | 50467034: | .35 | $5.36\times10^{-3}$ | - | - | - |
| ANX | EUR | - | *SALL1* | DEP-ANX | 52041336 | .70 | $\mathbf{1.24\times10^{-5}}$ | **.99** | rs728538 | *NA* |
| INS | EUR | - | *RBFOX1* | INS-DEP | Chr 16, BP | .64 | $\mathbf{8.55\times10^{-6}}$ | **.57** | rs10852673 | *NA* |
| DEP | EUR | 16:6303301:6343315 | *RBFOX1* | INS-ANX | 5782969: | .60 | $1.92\times10^{-4}$ | - | - | - |
| ANX | EUR | - | *RBFOX1* | DEP-ANX | 6446081 | .96 | $\mathbf{3.40\times10^{-7}}$ | **.97** | rs10852673 | *NA* |
| INS | EUR | **16:12259730:12464821** | *SHISA9* | INS-DEP | Chr 16, BP | .62 | $\mathbf{2.02\times10^{-5}}$ | **.99** | rs830733 | *NA* |
| DEP | Cross | **16:12101254:12601254** | *SHISA9* | INS-ANX | 12793150: | .15 | $3.44\times10^{-1}$ | - | - | - |
| ANX | EUR | - | *SHISA9* | DEP-ANX | 13893407 | .68 | $\mathbf{5.47\times10^{-5}}$ | .32 | - | - |
| INS | EUR | **18: 50358109:50908403** | *DCC* | INS-DEP | Chr 18, BP | .67 | $\mathbf{4.29\times10^{-5}}$ | **.61** | rs7231178 | INS → DEP |
| DEP | EUR | **18:50620087:50907127** | *DCC* | INS-ANX | 50372824: | .86 | $\mathbf{5.66\times10^{-6}}$ | **.90** | rs6508210 | INS → ANX |
| ANX | EUR | **18:50555931:50907127** | *DCC* | DEP-ANX | 51060986 | 1.0 | $\mathbf{2.81\times10^{-9}}$ | **.95** | rs8084351 | DEP → ANX |
| INS | EUR | - | - | INS-DEP | Chr 20, BP | .73 | $\mathbf{1.18\times10^{-5}}$ | **.79** | rs6131010 | INS → DEP |
| DEP | EUR | **20:44680412:44747947** | - | INS-ANX | 44072211: | .85 | $\mathbf{1.87\times10^{-6}}$ | **.98** | rs6032660 | ANX |
| ANX | EUR | **20:44680412:44747947** | - | DEP-ANX | 45673603 | .78 | $\mathbf{4.33\times10^{-6}}$ | **.98** | rs6131010 | DEP → ANX |
| INS | EUR | 20:50912495:51236973 | *TSHZ2* | INS-DEP | Chr 20, BP | .95 | $\mathbf{6.29\times10^{-6}}$ | **.76** | rs13043475 | *NA* |
| | | | | INS-ANX | 50653621: | - | - | - | - | - |
| DEP | Cross | 20:51338847:51838847 | *TSHZ2* | DEP-ANX | 51533750 | - | - | - | - | - |
| | | | | INS-DEP | Chr 20, BP | .62 | $9.47\times10^{-5}$ | - | - | - |
| ANX | EUR | - | *TSHZ2* | INS-ANX | 51533751: | .39 | $3.88\times10^{-3}$ | - | - | - |
| | | | | DEP-ANX | 52411532 | .80 | $\mathbf{1.52\times10^{-6}}$ | .00 | - | - |

mediated effect on the other) rather than horizontal pleiotropy or shared confounding (see Methods; Supplementary Table 7).

Out of the 25 and 7 unique variants colocalizing between only DEP-ANX or INS-ANX respectively, all but one (25 and 6 respectively) were assigned by PRISM to have a direct effect on INS or DEP. Given strong LHC-MR evidence for INS → ANX ($\beta$ = 0.65, SE=0.04, $p = 3.39\times10^{-61}$) and DEP → ANX ($\beta$ = 0.85, SE = 0.02, $p < 1.00\times10^{-300}$), these variants were subsequently classified as vertical pleiotropic of which genetic effects on ANX are mediated via DEP or INS. For the only variant that PRISM classified as having a direct effect on ANX (an INS-ANX colocalizing variant), we found no evidence for vertical pleiotropy with respect to INS, as LHC-MR did not support ANX→INS ($\beta$ = 0.07, SE = 0.08, $p$ = 0.37). The 28 unique variants colocalizing between DEP and INS were more often attributed to having a direct effect on INS (61%) than on DEP (39%). Given bidirectional evidence from LHC-MR (INS → DEP $\beta$ = 0.56, SE = 0.08, $p = 9.43\times10^{-12}$; DEP → INS $\beta$ = 0.30, SE=0.08, $p = 1.16\times10^{-4}$), all of these variants were classified as vertical pleiotropic. Overall, this suggests that the data for colocalizing variants are more compatible with INS and DEP being risk factors for ANX, while the relationship between INS and DEP shows a directional mixture across colocalizing variants.

Of the thirteen loci with colocalization evidence across all three traits, three loci were also assigned the same top SNP with the highest posterior probability (PP) of being the most likely shared causal variant across two traits (Table 1). rs868754 ($PP_{INS\text{-}DEP}$ = .47; $PP_{DEP\text{-}ANX}$ = .54) was assigned to have a direct effect on DEP in both pairwise PRISM analyses. Combined with the LHC-MR results described above, this led to classification as vertical pleiotropic (DEP → INS and DEP → ANX). Two pairwise PRISM analyses assigned rs6131010 ($PP_{INS\text{-}DEP}$ = .69; $PP_{DEP\text{-}ANX}$ = .70) to have a direct effect on INS and a direct effect on DEP, both of which could again be classified as pairwise vertical pleiotropic effects (INS → DEP and DEP → ANX respectively).

Two other loci with colocalization evidence across all three traits were assigned the same top SNP across all three traits (rs4702 all PP = 1.0; rs8180817 $PP_{INS\text{-}DEP}$ = .50, $PP_{INS\text{-}ANX}$ = .55, $PP_{DEP\text{-}ANX}$ = .40). Following the same pairwise methodology, rs4702 was classified vertical pleiotropic as INS → DEP, INS → ANX and DEP → ANX. Although one might be inclined to interpret these findings as a trivariate cascade (i.e. INS → DEP → ANX), we caution that we did not perform PRISM's trait wise analysis to integrate evidence across all three trait pairs simultaneously. This would require >30 traits for reliable inference[36] of pleiotropy, necessitating adding traits beyond the scope of this study. Additionally, it is debated whether in practice all the assumptions underlying Mendelian Randomization hold[50]. Violations of assumptions could have impacted the findings presented here.




*Figure 3.* **Number of overlapping effector genes across conditions.** We aggregated the identified effector genes (by FLAMES) across ancestries and across traits to give insight into the number of shared genes within each of these domains.

*Shared INS-DEP-ANX loci converge on the gene level*

To further explore the potential pleiotropy in these loci, we also assessed the level of pleiotropy on the gene-level. We predicted the effector genes of our shared loci using the FLAMES model, which integrates multimodal evidence (e.g. fine-mapping, annotations, eQTLs, co-expression) to identify the most likely causal gene[34]. Our aim was to examine how often shared loci also shared the same effector gene. We ran FLAMES with default settings (see Methods), on all overlapping GWS and LAVA loci. In total, 17 shared genes are predicted to be effector genes shared between INS, DEP and ANX (Table 1), 38 genes are uniquely shared between DEP and INS, 2 genes are uniquely shared between ANX and INS, and 32 genes are uniquely shared between ANX and DEP (Figure 3a; Supplementary Table 8). Out of all predicted effector genes, 60% of predicted genes are shared with at least one other trait (81% ANX, 80% INS, 71% DEP). However, this includes loci where FLAMES resolved only one trait and cannot with certainty predict an effector gene for the second trait and dilutes estimates of concordance. When considering overlapping loci where at least 2 genes are prioritized, these genes are concordant in 80% of overlapping loci. These results show that in the majority of resolved loci of ANX, DEP and INS, the GWAS signal converges into the same genes.

*Biological mechanisms of shared effector genes*

We performed Gene Ontology (GO)[51] enrichment analysis on three distinct set of genes; the 17 effector genes shared between all three phenotypes, 27 effector genes uniquely shared between ANX and DEP, and the 38 effector genes uniquely shared between INS and DEP. GO terms from the MSigDB database are

evaluated in a logistic regression framework (see Methods). We find significantly associated GO terms with all three sets of genes (Figure 4, Supplementary Table 9). The two shared effector genes between ANX and INS (*PDE4B, FTO*) were not tested for enrichment, but their function align with the enriched gene-sets (Supplementary Note 2). Interestingly, despite having no genes in common, the effector genes uniquely shared by ANX-DEP and by INS-DEP were enriched in the same gene-set on two occasions (Cellular Component GABAergic synapse; Biological Processes synaptic membrane adhesion), providing evidence for pathway-level convergence.

Effector genes uniquely shared between INS and DEP were furthermore enriched in processes related to cell adhesion and synaptic structuring, neuronal development and differentiation, synaptic signaling and plasticity. The effector genes uniquely shared between ANX and DEP were uniquely enriched in the (post)synaptic membrane, postsynaptic modulation of synaptic transmission and the regulation of GABAergic neurotransmission. Interestingly, the shared effector genes enriched in the GABAergic neuron, synaptic adhesion and the glutamatergic receptor complex gene sets are mostly involved in the regulation of tans-synaptic adhesion, receptor anchoring and signaling modulation, all of which fine-tune synaptic plasticity mechanisms[52–58]. Disturbances of synaptic plasticity have previously been reported in patients suffering from ANX, DEP and INS[59,60].




*Figure 4*. **Biological processes and cellular component enriched for true pleiotropic genes**. Effector genes that were shared among 2 or 3 traits were significantly enriched ($p < 1.90\times10^{-6}$) in Gene Ontology (GO) biological processes and cellular components. Node size reflects gene-set size, edges reflect pathway similarity scores (see Methods). Note that only one gene was uniquely shared between INS and ANX, and was therefore not tested for enrichment.

303 Many enriched gene-sets are strongly related to neurological development and synapse function
304 despite testing for enrichment in the broad array of gene-sets included in MSigDB. It is clear that with
305 processes such as the generation of neurons, neuron axonogenesis, neuron nucleus development and axon
306 guidance, as well as broader forebrain (i.e. striatum, subpallium and telencephalon) developmental
307 processes, general processes related to the development of the brain are implicated in the trivariate genetic
308 risk for INS-DEP-ANX (Figure 4). Additionally we find that processes related to viral infection and
309 inflammation are implicated, which converges with prior observations[61]. The genes involved in chemokine
310 2 and interleukin 12 production and viral processes (*FOXP1, HMGB1, FURIN* and *NCAM1)* that are shared
311 between INS-DEP-ANX can indicate immune processes or neurodevelopmental processes[62–64], as these
312 genes are also critical for neurodevelopment, growth and neuronal signalling. It is therefore unclear whether
313 these processes tag immune response, neuronal/neurodevelopmental processes, or both. We also note that
314 it is possible that genes now uniquely shared between INS-DEP, INS-ANX or DEP-ANX will become
315 shared across INS-DEP-ANX when GWAS power further increases.
316
317 *Shared effector genes are drug-targets for INS, DEP ANX through synaptic membrane mechanisms*
318 We investigated whether any of the effector genes shared between at least two of our three phenotypes have
319 been investigated as potential drug-targets for INS, DEP or ANX. We searched for overlap between our
320 genes of interests and genes which are the targets of approved or currently investigated drugs in the
321 OpenTargets database[65]. Of our 84 shared effector genes ($n_{\text{INS-DEP-ANX}}$ = 17, $n_{\text{DEP-ANX}}$ = 27, $n_{\text{INS-DEP}}$ = 38,
322 $n_{\text{INS-ANX}}$ = 2), nine (10.7%) were considered druggable, meaning that the gene product is modulated by an
323 administered exogenous compound. This is comparable with the fraction (7.5%) of genes that are the target
324 of a drug in the OpenTargets database (1,518 genes) out of the genes that could be prioritized by FLAMES
325 (20,260 genes). Interestingly, six of these nine druggable shared effector genes, namely *CACNA2D3*,
326 *DRD2*, *ESR1*, *GRIA1*, *GRM5* and *PDE4B*, have been previously investigated as targets in 43 drugs for INS,
327 DEP and/or ANX (Supplementary Table 11). All of these genes were identified as shared effectors for trait
328 pairs ($n_{\text{DEP-ANX}}$ = 3, $n_{\text{INS-DEP}}$ = 2, $n_{\text{INS-ANX}}$ = 1) instead of for the triad of INS-DEP-ANX. In the loci from
329 which these genes were mapped, the *ESR1* locus also had a colocalized variant (rs11756123) that was
330 classified as DEP → ANX pleiotropic by PRISM.
331 Cross-referencing the 43 drug-target pairs in the DrugBank database[66] highlighted that most ($n$ =
332 42) of these drugs are approved or in late stage clinical trials for ANX ($n$ = 17), DEP ($n$ = 13) or both ($n$ =
333 12 ;Supplementary Table 11). The majority of these drugs ($n$ = 35) are antagonists for dopamine receptor
334 D2, or glutamate receptor 1 or 5 (targeting *DRD2*, *GRIA1* or *GRM5* respectively)[66]. Two approved drugs
335 for depression that target *DRD2*, trimiparine and quetiapine, are also prescribed off-label for insomnia, and
336 for anxiety and insomnia, respectively[66]. The only drug with a sole indication for insomnia was atagabalin,

337 an inhibitor of voltage-dependent calcium channel α2δ3 (target gene *CACNA2D3*) reaching phase 2 clinical
338 trials. This means that the cross-disorder loci identified in this study that additionally share the same most
339 likely causal gene across INS, DEP and/or ANX include promising targets for drug development, since
340 previously tested targets that directly or indirectly impact synaptic transmission show transdiagnostic
341 effects across these conditions.

342 When contrasting the 6 druggable genes previously investigated as INS, DEP and/or ANX drug
343 targets against our enriched GO terms (Figure 4), we observed that the majority of the druggable genes
344 were part of the gene-sets involved in the (post)synaptic membrane, neuron-to-neuron synapse and neuron
345 spine (all 6 genes but *ESR1*). Other significantly enriched pathways or cellular components are likely only
346 minimally druggable through the genes we identified as shared effector genes, since these GO-terms
347 contained only one or two of the nine druggable genes. For example, two other large, related clusters of
348 enriched GO-terms (neuron generation and development, and synaptic adhesion and organization; see
349 Figure 4) contain *DRD2* and *GRM5,* as well as the glutamate receptor complex pathway (including *GRIA1)*,
350 and the regulation of GABAergic transmission pathway (including *DRD2*).

351 Overall, we find that a significant subset of the pathways we identified to be enriched for effector
352 genes shared between INS, DEP and ANX show promise for continued drug development, with many
353 investigated and approved drugs that target a shared effector gene having effects on multiple of these
354 disorders simultaneously.

355

356 **Discussion**

357 Insomnia, depression and anxiety disorders frequently co-occur and share a substantial proportion of their
358 genetic risk[12]. Most previous genetic studies have concentrated on shared risk between depression and
359 anxiety disorders[25], often omitting insomnia or restricting analyses to correlations of (overlapping) genetic
360 effects summarized across the genome[28,29]. This study includes the first multi-level investigation into the
361 shared molecular genetic signal across insomnia, depression and anxiety disorders. We find 55% genetic
362 overlap across all three traits with high correlations of effect sizes of overlapping variants ($r_{\text{g-shared}}$ = .63 -
363 .94). We are able to identify 195 unique genomic loci with statistical evidence of shared genetic signal
364 across (pairs of) traits. In our attempts to rule out instances of spurious pleiotropy by colocalization analyses
365 and effector gene prediction, we find strong evidence that the majority of these loci contain a causal variant
366 and/or shared effector gene shared between insomnia, depression, and anxiety disorders. Exploratory
367 analyses suggest that these shared causal variants are more consistent with models of vertical than
368 horizontal pleiotropy. Effector genes shared between different trait pairs converge on processes related to
369 the GABAergic synapse and synaptic membrane adhesion, and include targets of 12 previously investigated
370 and/or approved medications with an indication for at least two of our traits. Altogether this shows how

371 large-scale datasets and state of the art methodology can be used to identify molecular genetic liability
372 factors shared across insomnia, depression and anxiety disorders and highlight transdiagnostic biological
373 mechanisms that are potentially therapeutically actionable.

374 The current study applied a hierarchical multi-level framework, starting at the global level. Previous
375 work has suggested that the same subset of 10,000-15,000 variants seem to explain most of the SNP
376 heritability of major psychiatric disorders, with genetic differences between conditions arising mainly from
377 the directions and magnitudes of effects rather than from distinct loci[20]. In contrast, our Trivariate MiXeR
378 analysis shows that insomnia does not fully conform to this pattern. Although insomnia shares a substantial
379 proportion of its genetic architecture with depression and anxiety disorders, about one fifth of its genetic
380 signal appears distinct. This observation aligns with previous results, showing that loci from other traits
381 that colocalize with insomnia loci cluster into a psychiatric and metabolic component[16]. Future work could
382 investigate whether the genetic signal that is attributed to be unique to insomnia in this study, overlaps with
383 the genetics of metabolic traits. This may help to disentangle the genetic heterogeneity of insomnia and
384 inform stratified therapeutic approaches.

385 By applying the framework proposed here, we demonstrated that the majority of the shared genetic
386 signal found on the locus level consistently points to the same likely causal shared signal on the variant and
387 gene level. Specifically, we find that approximately two thirds of loci, when containing enough genetic
388 signal, colocalize between these three traits. Effector genes appear to be shared in approximately three
389 quarters of the investigated loci. This underscores that, generally, overlapping signal between these traits
390 can be considered shared pleiotropic signal. The ability to prune loci for spurious pleiotropy prior to
391 biological interpretation highlights the importance of incorporating colocalization and effector gene
392 prediction in cross-disorder genetic studies. Our genetic overlap, genetic correlation and vertical pleiotropy
393 directionality results are in line with previous studies[22,25,28,67].

394 In some instances, variant-level and gene-level results diverged. The prioritization of different
395 effector genes in the presence of evidence for a shared causal variant could be a result of difference in
396 overall fine-mapped credible sets despite significant colocalization, which could be a consequence of the
397 single variant assumption used. Alternatively, these differences could be due to different weighting of eQTL
398 evidence based on tissue relevance weighting step in FLAMES based on genome-wide MAGMA scores.
399 The differences could also be due to different PoPS scores for genes in the locus between these traits, which
400 could capture tissue/cell-type relevance of the GWAS signal based on the large quantity of tissue-specific
401 co-expression networks included in the features. This complexity underscores that, as emphasized in a
402 recent review[35], the loci we highlight should be considered a prioritized set of hypotheses for laboratory
403 validation, rather than definitive evidence of shared biology.

404 We find that a majority of the druggable genes that we identified as shared effector genes across
405 INS, DEP and ANX have previously been investigated as drug-targets for these conditions. Off-label
406 prescriptions that are used transdiagnostically indicate promise for continued drug development of
407 therapeutics targeting genes in e.g. GABA-ergic and glutamatergic signalling in the synapse. Of course,
408 drug development to address neurodevelopmental predispositions for ANX, DEP and INS is not feasible as
409 developmental processes generally precede diagnosis, yet altering synapse organization and plasticity in
410 adulthood might result in therapeutic benefits as suggested by these results. Given that the majority of
411 druggable genes are targets for approved or investigated INS, DEP and ANX medication, our approach
412 seems to be well powered to uncover pathways with likely transdiagnostic effects across these conditions.
413 The findings of this study should be considered within the context of a small total explained
414 variance of the genetic component investigated: we focus only on the genetic signal shared between traits,
415 that individually have very modest SNP-based heritability. Nevertheless, the relevance of the biological
416 processes we identify to be shared between insomnia, depression, and anxiety disorders based is supported
417 by previous pharmacological[68–70] and neurobiological[71–74] evidence. Our findings extend this literature by
418 showing that genes in these pathways are impacted by cross-disorder genetic risk variants. Gene-sets such
419 as the GABAergic synapse, regulation of (GABAergic) synaptic transmission, postsynaptic signalling, and
420 AMPA receptor complexes map plausibly onto the circuitry that normally silences locus coeruleus
421 noradrenergic neurons during rapid eye-movement (REM) sleep[75]. Incomplete locus coeruleus silencing is
422 hypothesized to relate to restless REM sleep and impaired overnight relief of emotional distress[76], and is
423 central in the leading models hypothesizing about the role of insomnia in anxiety- and stress-related
424 conditions[77]. At the same time, we note that genes with pleiotropic evidence across all three conditions were
425 also enriched in processes that are very typically found across psychiatric genetic literature[78], such as axon
426 guidance, and forebrain development. This may reflect more general neurodevelopmental liability rather
427 than mechanisms specifically shared between insomnia, depression and anxiety disorders. Recent evidence
428 also highlights that copy number variations shared across psychiatric conditions converge on pathways, but
429 diverge by cell type, brain region, and gene dosage[79]. This highlights another future direction when
430 focussing on divergence, rather than convergence, of shared genetic risk across insomnia, depression, and
431 anxiety disorders.
432 Important limitations of this work include a source of potential inflation in the observed genetic
433 overlap cannot be accounted for in this study, that is phenotype misclassification. As mentioned above, the
434 initial insomnia, depression, and anxiety disorders GWAS analyses could have been biased by a level of
435 misdiagnosis, unrecognized comorbidity resulting from ascertainment bias[80], or the use of both unscreened
436 and supernatural controls[81]. Future studies may address these potential sources of spurious pleiotropy by
437 careful longitudinal assessment, and the selection of control subjects screened to only exclude the target

conditions[82]. Similarly, underestimation of true genetic overlap can occur when the original GWAS summary statistics lack sufficient statistical power to detect genome-wide significant loci or significant local heritability. The GWAS of anxiety disorders was the least powered GWAS used in our study, which likely contributed to e.g. the smaller number of overlapping effector genes observed, which should not be interpreted as evidence of no overlap. Lastly, our exploratory findings that pairwise colocalized variants were attributable primarily to vertical pleiotropic effects should be interpretated with caution. Since we did not consider a large set (i.e. >30) of traits, we had limited statistical power to robustly evaluate the significance of the variant-trait associations, and lack a broader biological context that might reveal additional pleiotropic mechanisms[36]. Furthermore, there is valid criticism in the field that Mendelian Randomization is likely to violate its modelling assumptions which can bias the results[83]. Although simulations show that LHC-MR is robust to some violations of its modelling assumptions[49], we cannot prove that all assumptions are met. Definite conclusions on causal relationships require the triangulation of methods[84].

In conclusion, this study highlights a genetically interconnected basis for insomnia, depression and anxiety disorders across multiple levels of investigation. We provide a shortlist of pleiotropic variants, genes and pathways, offering potential candidates for future pathway-tailored therapeutic targets with transdiagnostic benefits.

## Methods

*GWAS summary statistics*

We obtained access to the largest available GWAS summary statistics of INS[16], ANX[17], and DEP[19,20] originally including participants from UK Biobank, 23andMe Research Institute, Million Veteran Program (MVP), Psychiatric Genetics Consortium (PGC), iPSYCH, FinnGen, and All of Us. Cross-ancestry summary statistics were available for ANX and DEP, including individuals from European (EUR), South Asian (SAS), East Asian (EAS), African (AFR) genetic ancestries. Only EUR individuals were included in the original GWAS of INS and compared to the EUR subset of ANX and DEP where necessary.

In accordance with recent methodological recommendations[85], effective sample size ($N_{\text{eff}}$) of each trait was first calculated for each individual sample included in the GWAS meta-analysis and subsequently summed. Essential columns (SNP, CHR, BP, A1, A2, Z, Neff) were extracted using https://github.com/precimed/python_convert (v.0.9.3). We defined genome-wide significant loci according to the FUMA definition[44].

469 *Genome-wide genetic overlap*

470 We applied Trivariate MiXeR[39] to disentangle the pattern of polygenic overlap among the EUR GWAS
471 summary statistics of INS[16], ANX[17], and DEP[20]. This recently released tool
472 (https://github.com/precimed/mix3r) allows for sample overlap and uses the 489 unrelated subjects of
473 European ancestry from 1000 Genomes phase 3 as LD reference panel[86] including SNPs with a minor allele
474 frequency (MAF) > .01 (n SNPs = 9,997,231). Following recommendations from the authors, we ignored
475 all inter-variant correlations with $r^2 < 0.05$, considering them to be very noisy in a sample of 489 subjects.
476 The MHC region (CHR6:BP25000000-34000000, GRCh37/hg19 build) was also excluded as
477 recommended by the authors[40]. The analysis was restricted to overlapping SNPs across summary statistics
478 ($N_{SNPs}$ = 3,122,674 ). Output parameters such as the proportion of non-null SNPs (polygenicity; $\pi$) where
479 multiplied by the total number of SNPs in the LD reference panel for interpretability.

480

481 *Genome-wide (partial) genetic correlations*

482 We computed genetic correlations ($r_g$) for INS, ANX and DEP summary statistics (EUR) using LD Score
483 Regression (LDSC)[42]. 1000 Genomes EUR[86] served as reference panel. LDSC analysis is restricted to
484 HapMap3 SNPs[87], ensuring a comparable set of SNPs available across traits with global genome coverage.
485 We additionally applied partial LDSC[43] with the same input and settings, which is an R-package extending
486 standard $r_g$ from LDSC (https://github.com/GEMINI-multimorbidity/partialLDSC). We used this tool to
487 condition the $r_g$ between DEP and ANX on INS, between INS and DEP on ANX, and between INS and
488 DEP on ANX.

489 *Local genetic correlations*

490 LAVA (Local Analysis of [co]Variant Association)[45] was used for local $r_g$ analysis, i.e. detecting genomic
491 regions of shared association between our three phenotypes. Sample overlap was estimated with LDSC as
492 recommended by the authors. The analysis was restricted to overlapping SNPs across summary statistics.
493 We used 2,495 predefined loci that are roughly independent and the 1000 Genomes reference data for
494 analysis with EUR GWAS summary statistics as provided on the GitHub repository
495 (https://github.com/josefin-werme/LAVA). Using the AFR GWAS summary statistics was not feasible due
496 to the absence of suitable reference panels, SAS and EAS summary statistics did not have sufficient
497 statistical power to run this analysis. For each region, traits devoid of local heritability ($p < 1\times10^{-4}$) were
498 filtered out before estimating bivariate $r_g$. This resulted in 580 EUR bivariate tests performed. We corrected
499 the alpha (α) level for statistical significance of local bivariate $r_g$ to $\alpha = (.5 / 582) = 8.59 \times10^{-5}$.

500 *Shared most likely causal SNPs*

501 We ran COLOC (v5.2.3[88]) under a single variant assumption, in all overlapping LAVA locus pairs and
502 GWS locus pairs. When only Z-scores were available, effect sizes ($\beta$) and standard errors ($SE$) were
503 estimated from Z-scores ($Z$), effective sample size ($N$) and the minor allele frequency ($p$) as:

504 (1) $$\beta = \frac{Z}{\sqrt{2p(1-p)(N+Z^2)}}$$

505 (2) $$SE = \frac{1}{\sqrt{2p(1-p)(N+Z^2)}}.$$

506

507 We deemed every locus-pair with a posterior probability > .5 for the case that both traits are associated and
508 share a single causal variant to be significantly colocalizing (H4).

509

510 *Pleiotropy analysis*

511 We ran the PRISM (Pleiotropic Relationships to Infer the SNP Model)[36] pairwise analysis pipeline to
512 classify colocalizing variants into models of horizontal, vertical or confounding pleiotropy. PRISM uses
513 results from Latent Heritable Confounder Mendelian Randomization (LHC-MR;
514 https://github.com/LizaDarrous/lhcMR)[49] as input, a bidirectional causal estimation model that accounts
515 for the presence of a heritable confounder (U). We ran LHC-MR with default settings, using EUR GWAS
516 summary statistics and the provided LD scores and HapMap3[87] SNPs as input. PRISM pairwise analysis
517 then uses LHC-MR's causal path estimates to parameterize the expected cross-trait covariance and assigns
518 each variant posterior probabilities (PP) across eight Gaussian components for each trait pair (X,Y): variant
519 has a direct effect 1) on neither X,Y or U, 2) on X, 3) on U, 4) on Y, 5) on X and U, 6) on X and Y, 7) on
520 Y and U, or 8) on X, Y and U. Variants with the highest PP for model 6 are classified as horizontal
521 pleiotropic, for model 3, 5, 7 or 8 as confounded. Variants with the highest PP for model 2 or 4 get classified
522 as vertical pleiotropic when there was significant causal inference ($p < (.05/3 = .0167)$) from LHC-MR for
523 mediation in that direction.

524

525 *Shared most likely causal genes*

526 We applied the FLAMES (Fine-mapped Locus Assessment Model of Effector geneS)[34] to identify the most
527 likely causal gene in each shared locus identified in our study. The framework consists of five steps, applied
528 on each condition (INS, ANX, DEP) with the available EUR and cross-ancestry summary statistics
529 (https://github.com/Marijn-Schipper/FLAMES). In short, FLAMES integrates SNP-to-gene evidence and
530 convergence-based evidence into a single prediction for each fine-mapped GWAS signal.

531 First, each locus was fine-mapped to obtain 95% credible sets. We ran PolyFun (POLYgenic
532 FUNctionally-informed fine-mapping)[89] on each locus with default settings except for keeping SNPs in the

533 HLA region. We extracted the estimated prior causal probabilities for the SNPs, which were then used by
534 SuSiE (Sum of Single Effects)[90] to perform non-functionally informed fine-mapping assuming one causal
535 variant per locus. Second, we ran MAGMA[91] as implemented in the CoMorMent Containers v1.8.1[92] to
536 obtain gene-level *z*-scores. We then ran MAGMA tissue type analysis using these *z*-scores on the
537 preformatted GTEx[93] tissue expression file provided by the FLAMES authors. Third, Polygenic Priority
538 Score (PoPS; v0.2)[94] was used to compute convergence-based gene prioritization scores. The FLAMES
539 authors provided PoPS features including an extensive set of public bulk and single-cell expression datasets
540 and predicted protein-protein interactions (https://zenodo.org/records/12635505). We intentionally
541 excluded biological pathways in the PoPs features, aiming to prevent circularity in downstream pathway
542 analyses on FLAMES prioritized genes[34]. Fourth, we annotated credible sets with FLAMES annotate,
543 which creates gene-level evidence scores for genes within 750kb of the centroids of credible sets from SNP-
544 to-gene annotations, MAGMA Z-scores and PoPS scores. We used the FLAMES predictive model to
545 predict the effector gene of each credible set from the generated annotations.
546 Note that a few loci will be left unresolved by FLAMES in the case of (1) unsuccessful fine-
547 mapping due to complex LD (e.g. MHC region), (2) no proximal genes (<750 kilobases) from the credible
548 set, or (3) an estimated cumulative precision < 0.75.
549
550 *Pathway analysis*
551 We performed pathway analyses to find patterns of enrichment of effector genes shared across INS, DEP
552 and ANX, and of effector genes uniquely shared across two traits. As previously described in the FLAMES
553 paper[34], pathway membership of genes was encoded in a binary vector, and FLAMES prioritized genes
554 were also encoded in a binary vector. We subsequently performed logistic regression, regressing the
555 FLAMES genes of a phenotype on the pathways. Pathways were defined as Gene Ontology (GO)[51]
556 Biological Processes and Cellular Components ($n$ = 8,760) from MSigDB (v.2023.1). All significant ($p <$
557 $(.05/8{,}760)/3 = 1.90\times10^{-6}$) non-zero regression coefficients where ≥2 genes overlapped between the gene-
558 set and the FLAMES effector genes were visualized as a graph using Cytoscape[95] and EnrichmentMap[65].
559 Pathway similarity scores (Jaccard and overlap combined coefficient = .5) were used as edges between the
560 gene-sets (see the Nature Protocol by Reimand et al.[97] for further details).
561
562 *Finding drug targets for effector genes and mapping them to indications*
563 To identify currently druggable shared effector genes, we downloaded the OpenTargets known drug dataset
564 (version 25.12; https://ftp.ebi.ac.uk/pub/databases/opentargets/platform/25.12/output/known_drug/). We
565 extracted all genes with an indication for anxiety, insomnia or depression. We manually cross-referenced

566 the 43 drug-target pairs in the DrugBank database[66], noting whether the drug had been approved or
567 investigated in clinical trials for any of our phenotypes of interest.
568
569 **Data availability**
570 This study relies on previously published GWAS summary statistics as cited in the main text. Access to
571 23andMe summary statistics requires application via https://research.23andme.com/dataset-access/. The
572 data generated in the current manuscript is available in the Supplementary Tables.
573
574 **Code availability**
575 The code to obtain the results presented in this manuscript will be available via
576 https://github.com/EPTissink/ upon publication.
577
578 **Acknowledgements**
579 This work has received funding from ZonMw, The Hague, The Netherlands, project 09120011910032
580 REMOVE, and from the European Union: the European Research Council (ERC), Brussels, Belgium,
581 Advanced Grant 101055383 OVERNIGHT (E.T. and E.J.W.V.S.). M.S. was funded by NWO Gravitation:
582 BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (Grant No. 024.004.012). Views and
583 opinions expressed are however those of the author(s) only and do not necessarily reflect those of the
584 European Union or the European Research Council Executive Agency. Neither the European Union nor the
585 granting authority can be held responsible for them. The funders had no role in the design, data collection,
586 data analysis, and reporting of this study. We would like to thank Marie Verbanck and Martin Tournaire
587 for insightful discussions. We would like to thank the research participants and employees of 23andMe
588 Research Institute for making this work possible.
589
590 **Author Contributions**
591 M.S.: Formal Analysis, Visualization, Writing – Original. A.A.S.: Software, Writing – Review & Editing.
592 C.R.: Software, Writing – Review & Editing. E.F.: Resources, Writing – Review & Editing. R.P.:
593 Resources; Writing – Review & Editing. D.P.: Conceptualization, Writing – Review & Editing. E.J.W.v.S.:
594 Conceptualization, Funding Acquisition, Writing – Review & Editing. E.T.: Conceptualization, Data
595 Curation, Formal Analysis, Supervision, Visualization, Writing – Original.

## Conflicts of interest

M.S., A.A.S., C.R., E.F., D.P., E.J.W.v.S., and E.T. declare no conflict of interest. R.P. received an honorarium from Karger Publishers for his work on Complex Psychiatry and a research grant from Alkermes outside the scope of this manuscript.

## References


1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. (DSM-5). https://cir.nii.ac.jp/crid/1573950399819987840 (2013).
2. Soehner, A. M. & Harvey, A. G. Prevalence and Functional Consequences of Severe Insomnia Symptoms in Mood and Anxiety Disorders: Results from a Nationally Representative Sample. *Sleep* **35**, 1367–1375 (2012).
3. Ohayon, M. M. & Roth, T. Place of chronic insomnia in the course of depressive and anxiety disorders. *J. Psychiatr. Res.* **37**, 9–15 (2003).
4. Wittchen, H. U. *et al.* The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur. Neuropsychopharmacol.* **21**, 655–679 (2011).
5. Cuijpers, P. The Challenges of Improving Treatments for Depression. *JAMA* **320**, 2529–2530 (2018).
6. Roth, T. *et al.* Sleep Problems, Comorbid Mental Disorders, and Role Functioning in the National Comorbidity Survey Replication. *Biol. Psychiatry* **60**, 1364–1371 (2006).
7. Leerssen, J. *et al.* Treating Insomnia with High Risk of Depression Using Therapist-Guided Digital Cognitive, Behavioral, and Circadian Rhythm Support Interventions to Prevent Worsening of Depressive Symptoms: A Randomized Controlled Trial. *Psychother. Psychosom.* **91**, 168–179 (2022).
8. de Lange, S. C. *et al.* Multimodal brain imaging of insomnia, depression and anxiety symptoms indicates transdiagnostic commonalities and differences. *Nat. Ment. Health* **3**, 517–529 (2025).
9. Ruberto, V. L., Jha, M. K. & Murrough, J. W. Pharmacological Treatments for Patients with Treatment-Resistant Depression. *Pharmaceuticals* **13**, 116 (2020).
10. Ansara, E. D. Management of treatment-resistant generalized anxiety disorder. *Ment. Health Clin.* **10**, 326–334 (2020).
11. Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. *Nature* **629**, 624–629 (2024).
12. Lind, M. J. *et al.* An examination of the etiologic overlap between the genetic and environmental influences on insomnia and common psychopathology. *Depress. Anxiety* **34**, 453–462 (2017).

13. Madrid-Valero, J. J., Rubio-Aparicio, M., Gregory, A. M., Sánchez-Meca, J. & Ordoñana, J. R. The heritability of insomnia: Systematic review and meta-analysis of twin studies. *Sleep Med. Rev.* **58**, 101437 (2021).
14. Sullivan, P. F., Michael Neale, F. C. & Kendler, K. S. *Reviews and Overviews Genetic Epidemiology of Major Depression: Review and Meta-Analysis*. *Am J Psychiatry* vol. 157 10 http://views.vcu.edu/pub/mx/examples/mdreview. (2000).
15. Hettema, J. M., Neale, M. C. & Kendler, K. S. A Review and Meta-Analysis of the Genetic Epidemiology of Anxiety Disorders. *Am. J. Psychiatry* **158**, 1568–1578 (2001).
16. Watanabe, K. *et al.* Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. *Nat. Genet.* **54**, 1125–1132 (2022).
17. Friligkou, E. *et al.* Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study. *Nat. Genet.* **56**, 2036–2045 (2024).
18. Strom, N. I. *et al.* Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. 2024.07.03.24309466 Preprint at https://doi.org/10.1101/2024.07.03.24309466 (2024).
19. Meng, X. *et al.* Multi-ancestry genome-wide association study of major depression aids locus discovery, fine mapping, gene prioritization and causal inference. *Nat. Genet.* **56**, 222–233 (2024).
20. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. *Nat. Med.* **29**, 1832–1844 (2023).
21. Jansen, P. R. *et al.* Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat. Genet.* **51**, 394–403 (2019).
22. Romero, C. *et al.* Exploring the genetic overlap between twelve psychiatric disorders. *Nat. Genet.* **54**, 1795–1802 (2022).
23. Wray, N. R., Lee, S. H. & Kendler, K. S. Impact of diagnostic misclassification on estimation of genetic correlations using genome-wide genotypes. *Eur. J. Hum. Genet.* **20**, 668–674 (2012).
24. Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis. *Nat. Genet.* **54**, 548–559 (2022).
25. Tesfaye, M. *et al.* Identification of Novel Genomic Loci for Anxiety and Extensive Genetic Overlap with Psychiatric Disorders. *medRxiv* 2023.09.01.23294920 (2024) doi:10.1101/2023.09.01.23294920.
26. The Brainstorm Consortium *et al.* Analysis of shared heritability in common disorders of the brain. *Science* **360**, eaap8757 (2018).
27. Lee, P. H. *et al.* Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell* **179**, 1469-1482.e11 (2019).

662 28. O'Connell, K. S. *et al.* Characterizing the Genetic Overlap Between Psychiatric Disorders and Sleep-
663 Related Phenotypes. *Biol. Psychiatry* **90**, 621–631 (2021).
664 29. Baranova, A., Cao, H. & Zhang, F. Shared genetic liability and causal effects between major
665 depressive disorder and insomnia. *Hum. Mol. Genet.* **31**, 1336–1345 (2022).
666 30. Fisher, R. A. The Correlation between Relatives on the Supposition of Mendelian Inheritance. *Trans.*
667 *R. Soc. Edinb.* **52**, 399–433 (1919).
668 31. Falconer, D. S. *Introduction to Quantitative Genetics.* (Pearson Education India, 1996).
669 32. Lynch, M. & Walsh, B. *Genetics and Analysis of Quantitative Traits*. (Sinauer, 1998).
670 33. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association
671 Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383 (2014).
672 34. Schipper, M. *et al.* Prioritizing effector genes at trait-associated loci using multimodal evidence. *Nat.*
673 *Genet.* **57**, 323–333 (2025).
674 35. Mackay, T. F. C. & Anholt, R. R. H. Pleiotropy, epistasis and the genetic architecture of quantitative
675 traits. *Nat. Rev. Genet.* 1–19 (2024) doi:10.1038/s41576-024-00711-3.
676 36. Tournaire, M., Nouira, A., Rozenholc, Y. & Verbanck, M. Inferring genetic variant causal network
677 by leveraging pleiotropy. 2024.06.01.24308193 Preprint at
678 https://doi.org/10.1101/2024.06.01.24308193 (2024).
679 37. Tesfaye, M. *et al.* Comorbidity alters the genetic relationship between anxiety disorders and major
680 depression. 2024.11.19.24317523 Preprint at https://doi.org/10.1101/2024.11.19.24317523 (2024).
681 38. Pasman, J. A. *et al.* An encompassing Mendelian randomization study of the causes and
682 consequences of major depressive disorder. *Nat. Ment. Health* 1–10 (2025) doi:10.1038/s44220-025-
683 00471-x.
684 39. Shadrin, A. A. *et al.* Distinct patterns of genetic overlap among multimorbidities revealed with
685 trivariate MiXeR. *Genome Med.* **17**, 106 (2025).
686 40. Holland, D. *et al.* Beyond SNP heritability: Polygenicity and discoverability of phenotypes estimated
687 with a univariate Gaussian mixture model. *PLoS Genet.* **16**, (2020).
688 41. Frei, O. *et al.* Bivariate causal mixture model quantifies polygenic overlap between complex traits
689 beyond genetic correlation. *Nat. Commun.* **10**, (2019).
690 42. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.*
691 **47**, 1236–1241 (2015).
692 43. Mounier, N. *et al.* Genetics identifies obesity as a shared risk factor for co-occurring multiple long-
693 term conditions. 2024.07.10.24309772 Preprint at https://doi.org/10.1101/2024.07.10.24309772
694 (2024).

44. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, (2017).
45. Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated framework for local genetic correlation analysis. *Nat. Genet.* **54**, 274–282 (2022).
46. Uffelmann, E., Leeuw, C. de & Posthuma, D. Local Genetic Sex Differences in Quantitative Traits. 2023.05.04.539410 Preprint at https://doi.org/10.1101/2023.05.04.539410 (2023).
47. Werme, J. *et al.* Local genetic correlation analysis links depression with molecular and brain imaging endophenotypes. *medRxiv* https://doi.org/10.1101/2023.03.01.23286613 (2023) doi:10.1101/2023.03.01.23286613.
48. Tissink, E. *et al.* The Genetic Architectures of Functional and Structural Connectivity Properties within Cerebral Resting-State Networks. *eNeuro* **10**, (2023).
49. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of bi-directional causal effects and heritable confounding from GWAS summary statistics. *Nat. Commun.* **12**, 7274 (2021).
50. de Leeuw, C., Savage, J., Bucur, I. G., Heskes, T. & Posthuma, D. Understanding the assumptions underlying Mendelian randomization. *Eur. J. Hum. Genet.* **30**, 653–660 (2022).
51. Carbon, S. *et al.* The Gene Ontology resource: Enriching a GOld mine. *Nucleic Acids Res.* **49**, D325–D334 (2021).
52. Kleijer, K. T. E., Zuko, A., Shimoda, Y., Watanabe, K. & Burbach, J. P. H. Contactin-5 expression during development and wiring of the thalamocortical system. *Neuroscience* **310**, 106–113 (2015).
53. Kim, J. *et al.* MDGA1 negatively regulates amyloid precursor protein–mediated synapse inhibition in the hippocampus. *Proc. Natl. Acad. Sci.* **119**, e2115326119 (2022).
54. Katzman, A. & Alberini, C. M. NLGN1 and NLGN2 in the prefrontal cortex: their role in memory consolidation and strengthening. *Curr. Opin. Neurobiol.* **48**, 122–130 (2018).
55. Babaev, O. *et al.* IgSF9b regulates anxiety behaviors through effects on centromedial amygdala inhibitory synapses. *Nat. Commun.* **9**, 5400 (2018).
56. Hruska, M. & Dalva, M. B. Ephrin regulation of synapse formation, function and plasticity. *Mol. Cell. Neurosci.* **50**, 35–44 (2012).
57. Lie, E., Li, Y., Kim, R. & Kim, E. SALM/Lrfn Family Synaptic Adhesion Molecules. *Front. Mol. Neurosci.* **11**, (2018).
58. Kim, S., Shin, J. J., Kang, M., Yi, Y. & Kim, E. Synaptic and Non-Synaptic Functions of PTPRD: A Receptor Tyrosine Phosphatase at the Crossroads of Neural Circuitry and Metabolism. *J. Neurochem.* **169**, e70292 (2025).
59. Sha, Z., Xu, J., Li, N. & Li, O. Regulatory Molecules of Synaptic Plasticity in Anxiety Disorder. *Int. J. Gen. Med.* **16**, 2877–2886 (2023).

60. Zhang, M.-Q., Li, R., Wang, Y.-Q. & Huang, Z.-L. Neural Plasticity Is Involved in Physiological Sleep, Depressive Sleep Disturbances, and Antidepressant Treatments. *Neural Plast.* **2017**, 5870735 (2017).
61. Prather, A. A., Vogelzangs, N. & Penninx, B. W. J. H. Sleep duration, insomnia, and markers of systemic inflammation: Results from the Netherlands Study of Depression and Anxiety (NESDA). *J. Psychiatr. Res.* **60**, 95–102 (2015).
62. Han, V. X., Patel, S., Jones, H. F. & Dale, R. C. Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. *Nat. Rev. Neurol.* **17**, 564–579 (2021).
63. Zhang, Y. *et al.* The emerging role of furin in neurodegenerative and neuropsychiatric diseases. *Transl. Neurodegener.* **11**, 39 (2022).
64. Sytnyk, V., Leshchyns'ka, I. & Schachner, M. Neural Cell Adhesion Molecules of the Immunoglobulin Superfamily Regulate Synapse Formation, Maintenance, and Function. *Trends Neurosci.* **40**, 295–308 (2017).
65. Buniello, A. *et al.* Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. *Nucleic Acids Res.* **53**, D1467–D1475 (2025).
66. Knox, C. *et al.* DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res.* **52**, D1265–D1275 (2024).
67. Pasman, J. A. *et al.* Causes and consequences of major depressive disorder: An encompassing Mendelian randomization study. 2024.05.21.24307678 Preprint at https://doi.org/10.1101/2024.05.21.24307678 (2024).
68. Cutler, A. J., Mattingly, G. W. & Maletic, V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. *Transl. Psychiatry* **13**, 228 (2023).
69. Krystal, J. H., Kavalali, E. T. & Monteggia, L. M. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. *Neuropsychopharmacology* **49**, 41–50 (2024).
70. Lucassen, P. J. *et al.* Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. *Eur. Neuropsychopharmacol.* **20**, 1–17 (2010).
71. Duman, R. S., Sanacora, G. & Krystal, J. H. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. *Neuron* **102**, 75–90 (2019).
72. Duman, R. S., Aghajanian, G. K., Sanacora, G. & Krystal, J. H. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. *Nat. Med.* **22**, 238–249 (2016).
73. Bisaz, R., Conboy, L. & Sandi, C. Learning under stress: A role for the neural cell adhesion molecule NCAM. *Neurobiol. Learn. Mem.* **91**, 333–342 (2009).

763 74. Manitt, C. *et al.* dcc orchestrates the development of the prefrontal cortex during adolescence and is
764 altered in psychiatric patients. *Transl. Psychiatry* **3**, e338–e338 (2013).
765 75. Breton-Provencher, V. & Sur, M. Active control of arousal by a locus coeruleus GABAergic circuit.
766 *Nat. Neurosci.* **22**, 218–228 (2019).
767 76. Wassing, R., Benjamins, J. S., Talamini, L. M., Schalkwijk, F. & Van Someren, E. J. W. Overnight
768 worsening of emotional distress indicates maladaptive sleep in insomnia. *Sleep* **42**, (2019).
769 77. Van Someren, E. J. W. Brain mechanisms of insomnia: new perspectives on causes and
770 consequences. *Physiol. Rev.* **101**, 995–1046 (2021).
771 78. Lee, P. H. *et al.* Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight
772 Psychiatric Disorders. *Cell* **179**, 1469-1482.e11 (2019).
773 79. Engchuan, W. *et al.* Psychiatric disorders converge on common pathways but diverge in cellular
774 context, spatial distribution, and directionality of genetic effects. 2025.07.11.25331381 Preprint at
775 https://doi.org/10.1101/2025.07.11.25331381 (2025).
776 80. Smoller, J. W., Lunetta, K. L. & Robins, J. Implications of comorbidity and ascertainment bias for
777 identifying disease genes. *Am. J. Med. Genet.* **96**, 817–822 (2000).
778 81. Kendler, K. S., Chatzinakos, C. & Bacanu, S.-A. The impact on estimations of genetic correlations by
779 the use of super-normal, unscreened, and family-history screened controls in genome wide case–
780 control studies. *Genet. Epidemiol.* **44**, 283–289 (2020).
781 82. Lee, P. H., Feng, Y.-C. A. & Smoller, J. W. Pleiotropy and Cross-Disorder Genetics Among
782 Psychiatric Disorders. *Biol. Psychiatry* **89**, 20–31 (2021).
783 83. de Leeuw, C., Savage, J., Bucur, I. G., Heskes, T. & Posthuma, D. Understanding the assumptions
784 underlying Mendelian randomization. *Eur. J. Hum. Genet.* **30**, 653–660 (2022).
785 84. Treur, J. L., Lukas, E., Sallis, H. M. & Wootton, R. E. A guide for planning triangulation studies to
786 investigate complex causal questions in behavioural and psychiatric research. *Epidemiol. Psychiatr.*
787 *Sci.* **33**, e61 (2024).
788 85. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M. Pervasive
789 Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide Association Study
790 Meta-analysis: A Simple Solution. *Biol. Psychiatry* **93**, 29–36 (2023).
791 86. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
792 87. Altshuler, D. M. *et al.* Integrating common and rare genetic variation in diverse human populations.
793 *Nature* **467**, 52–58 (2010).
794 88. Pullin, J. M. & Wallace, C. Variant-specific priors in colocalisation analysis. 2024.08.21.608957
795 Preprint at https://doi.org/10.1101/2024.08.21.608957 (2024).

796 89. Weissbrod, O. *et al.* Functionally-informed fine-mapping and polygenic localization of complex trait
797 heritability. https://doi.org/10.1101/807792 (2020) doi:10.1101/807792.
798 90. Wang, G., Sarkar, A., Carbonetto, P., Stephens, M. & Matthew Stephens, C. A simple new approach
799 to variable selection in regression, with application to genetic fine-mapping.
800 https://doi.org/10.1101/501114 doi:10.1101/501114.
801 91. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis
802 of GWAS Data. *PLoS Comput. Biol.* **11**, (2015).
803 92. Akdeniz, B. C. *et al.* COSGAP: COntainerized Statistical Genetics Analysis Pipelines. *Bioinforma.*
804 *Adv.* **4**, vbae067 (2024).
805 93. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
806 94. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes underlying
807 complex traits and diseases.
808 95. Shannon, P. *et al.* Cytoscape: A software Environment for integrated models of biomolecular
809 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
810 96. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: A network-based
811 method for gene-set enrichment visualization and interpretation. *PLoS ONE* **5**, (2010).
812 97. Reimand, J. *et al.* Pathway enrichment analysis and visualization of omics data using g:Profiler,
813 GSEA, Cytoscape and EnrichmentMap. *Nat. Protoc.* **14**, 482–517 (2019).
814